Myasthenia Gravis — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Inebilizumab (Uplizna) for myasthenia gravis.
— The Medical letter on drugs and therapeutics (6 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42348773/
- 2.
MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificity.
Vergoossen Dana L E et al. — Journal of autoimmunity (2 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42391746/
- 3.
Late-Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive Challenges.
Latini E et al. — Muscle & nerve (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42387879/
- 4.
Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.
Verza Massimiliano Ugo et al. — Muscle & nerve (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42387811/
- 5.
Muscle-Specific Kinase Signaling and Its Therapeutic Potential.
Jensen Stine Marie et al. — Muscle & nerve (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42387809/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Recruiting — Phase 3 — Vor Biopharma
https://clinicaltrials.gov/study/NCT06456580
- 2.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 3.
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Recruiting — Phase 1 — Kite, A Gilead Company
https://clinicaltrials.gov/study/NCT07304154
- 4.
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Recruiting — Phase 2 — Kyverna Therapeutics
https://clinicaltrials.gov/study/NCT06193889
- 5.
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Recruiting — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06744920
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myasthenia Gravis
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the connection between nerves and muscles, causing muscle weakness that worsens with activity. It affects approximately 5,000-7,000 Australians. A rapidly expanding range of treatments, including new targeted therapies, can now achieve good symptom control for many patients.
Most Recent Research
Common Questions
What is Myasthenia Gravis?
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the connection between nerves and muscles, causing muscle weakness that worsens with activity. It affects approximately 5,000-7,000 Australians. A rapidly expanding range of treatments, including new targeted therapies, can now achieve good symptom control for many patients.
How many clinical trials are available for Myasthenia Gravis?
RareWays currently indexes 275 clinical trials for Myasthenia Gravis, of which 98 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Myasthenia Gravis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Myasthenia Gravis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.